- Home
- MHO vs NVCR Comparison
MHO vs NVCR Comparison
Compare MHO & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHO
- NVCR
- Stock Information
- Founded
- MHO 1976
- NVCR 2000
- Country
- MHO United States
- NVCR Jersey
- Employees
- MHO N/A
- NVCR N/A
- Industry
- MHO Homebuilding
- NVCR Medical/Dental Instruments
- Sector
- MHO Consumer Discretionary
- NVCR Health Care
- Exchange
- MHO Nasdaq
- NVCR Nasdaq
- Market Cap
- MHO 3.6B
- NVCR 3.2B
- IPO Year
- MHO 1986
- NVCR 2015
- Fundamental
- Price
- MHO $137.39
- NVCR $26.60
- Analyst Decision
- MHO Buy
- NVCR Buy
- Analyst Count
- MHO 3
- NVCR 5
- Target Price
- MHO $197.50
- NVCR $33.40
- AVG Volume (30 Days)
- MHO 322.7K
- NVCR 946.5K
- Earning Date
- MHO 01-29-2025
- NVCR 02-27-2025
- Dividend Yield
- MHO N/A
- NVCR N/A
- EPS Growth
- MHO 8.04
- NVCR N/A
- EPS
- MHO 18.62
- NVCR N/A
- Revenue
- MHO $4,271,981,000.00
- NVCR $577,738,000.00
- Revenue This Year
- MHO $11.89
- NVCR $19.13
- Revenue Next Year
- MHO $4.70
- NVCR $5.38
- P/E Ratio
- MHO $7.49
- NVCR N/A
- Revenue Growth
- MHO N/A
- NVCR 14.63
- 52 Week Low
- MHO $109.92
- NVCR $11.70
- 52 Week High
- MHO $176.18
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- MHO 48.26
- NVCR 47.12
- Support Level
- MHO $135.10
- NVCR $25.46
- Resistance Level
- MHO $141.94
- NVCR $27.47
- Average True Range (ATR)
- MHO 3.77
- NVCR 1.26
- MACD
- MHO 1.95
- NVCR -0.59
- Stochastic Oscillator
- MHO 76.64
- NVCR 28.63
About MHO M/I Homes Inc.
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprise the most significant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.